ESR1 and breast carcinoma: Transcriptional silencing of ERα by DNA methylation has been well documented in patients with recurrent breast cancer who have received tamoxifen therapy, whereas mutations within the open reading frame of ER in patients are not common although some mutations in the ER have been examined in resistant cell lines [6], [54].